Cryotext™ is used as replacement tissue that is inserted or implanted into the joint and other injured areas.
Typically the joint tissue is missing or damaged severely and requires new or additional tissue products to create conditions that encourage regeneration of anatomical infrastructure.
Cryotext™ does not use any material obtained directly from the embryo or fetus. Cryotext™ has higher concentrations of peptides, hyaluronic acid and growth factors when compared to amniotic fluid suspensions. Cryotext™ is processed from human tissue, donated following full term, c-section deliveries, in accordance with the FDA.
Cryotext™ is regulated as a human cell, tissue or cellular tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act.